Home > Insider Trading > Filing (0001209191-19-044032)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1685071	Dova Pharmaceuticals Inc.	DOVA	Pharmaceutical Preparations (2834)	813858961

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1709417	Kevin Laliberte	C/O Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham NC 27707	Sr. Vp, Product Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-07-31	1,389	$15.97	11,557	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2019-07-30	10,000	$0.00	10,000	$16.08

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,000		2029-07-30	No	4	A	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $16.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
One-fourth (1/4th) of the shares vest July 30, 2020, and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter, subject to the Reporting Persons continuous service as of each such date.